# US 2006/0154310 A1 · Diagnosis and therapy of cancer using SGP28-related molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154310 A1
- Document ID: US20060154310A1
- Status: Published application
- Kind: A1
- Application number: 10/992,946
- Filed: 2004-11-18
- Published: 2006-07-13
- Earliest claimed: 1999-10-28
- Assignees: Agensys, Inc.
- Inventors: Rene Hubert; Arthur Raitano; Daniel Afar; Steve Mitchell; Mary Faris; Aya Jakobovits
- Web page: https://patentgrep.com/patent/US20060154310A1

## CPC

- G01N 33/57555: of the prostate
- C07K 14/47: from mammals
- C07K 16/18: against material from animals or humans
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2319/00: Fusion polypeptide
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/154: Methylation markers
- C12Q 2600/158: Expression markers
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer which utilize isolated polynucleotides corresponding to the human SGP28 gene, proteins encoded by the SGP28 gene and fragments thereof, and antibodies capable of specifically recognizing and binding to SGP28 proteins.

## Claims

### Claim 1

A method of detecting the presence of a cancer expressing SGP28 protein that comprises determining the level of SGP28 protein expressed by cells in a test tissue sample from an individual and comparing the level so determined to the level of SGP28 expressed in a corresponding normal sample, the presence of elevated SGP28 protein in the test sample relative to the normal sample providing an indication of the presence of such cancer in the individual.

### Claim 2 (depends on 1)

The method of claim 1, wherein determining the level of SGP28 protein expressed by the cells comprises contacting the cells with an antibody that specifically binds SGP28 protein.

### Claim 3 (depends on 2)

The method of claim 2, wherein the antibody comprises a polyclonal antibody.

### Claim 4 (depends on 2)

The method of claim 2, wherein the antibody comprises a monoclonal antibody.

### Claim 5

A method of monitoring SGP28 gene products comprising determining the status of SGP28 gene products expressed by cells in a test tissue sample from an individual and comparing the status so determined to the status of SGP28 gene products in a corresponding normal sample, the presence of altered status of SGP28 gene products in the test sample relative to the normal sample providing an indication of dysregulated cell growth within the individual.

### Claim 6

A method of examining a biological sample for evidence of dysregulated cellular growth comprising comparing the status of SGP28 in the biological sample to the status of SGP28 in a corresponding normal sample, wherein alterations in the status of SGP28 in the biological sample are associated with dysregulated cellular growth.

### Claim 7 (depends on 6)

The method of claim 6, wherein the status of SGP28 in the biological sample is evaluated by examining levels of SGP28 mRNA expression or levels of SGP28 protein expression.

### Claim 8 (depends on 6)

The method of claim 6, wherein an alteration in the status of SGP28 is identified by the presence of SGP28 expressing cells in a biological sample from a tissue in which SGP28 expressing cells are normally absent.

### Claim 9

A method of diagnosing the presence of cancer in an individual comprising:
(a) determining the level of SGP28 mRNA expressed in a test sample obtained from the individual; and
(b) comparing the level so determined to the level of SGP28 mRNA expressed in a comparable known normal tissue sample, the presence of elevated SGP28 mRNA expression in the test sample relative to the normal tissue sample providing an indication of the presence of cancer.

### Claim 10

A method of diagnosing the presence of cancer in an individual comprising:
(a) determining the level of SGP28 protein expressed in a test sample obtained from the individual; and
(b) comparing the level so determined to the level of SGP28 protein expressed in a comparable known normal tissue sample,
the presence of elevated SGP28 protein in the test sample relative to the normal tissue sample providing an indication of the presence of cancer.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cancer is prostate or colon cancer, and the test and normal tissue samples are selected from the group consisting of prostate tissue, colon tissue, lymphatic tissue, serum, blood or semen.

### Claim 12 (depends on 10)

The method of claim 10, wherein determining the level of SGP28 protein expressed in the test sample comprises contacting the sample with an antibody that specifically binds SGP28 protein.

### Claim 13 (depends on 12)

The method of claim 12, wherein the antibody comprises a polyclonal antibody.

### Claim 14 (depends on 12)

The method of claim 12, wherein the antibody comprises a monoclonal antibody.

### Claim at position 15

15-38. (canceled)
